158 related articles for article (PubMed ID: 38316287)
1. Prostate cancer: Novel genetic and immunologic biomarkers.
Samare-Najaf M; Kouchaki H; Moein Mahini S; Saberi Rounkian M; Tavakoli Y; Samareh A; Karim Azadbakht M; Jamali N
Clin Chim Acta; 2024 Mar; 555():117824. PubMed ID: 38316287
[TBL] [Abstract][Full Text] [Related]
2. Urinary RNA-based biomarkers for prostate cancer detection.
Martignano F; Rossi L; Maugeri A; Gallà V; Conteduca V; De Giorgi U; Casadio V; Schepisi G
Clin Chim Acta; 2017 Oct; 473():96-105. PubMed ID: 28807541
[TBL] [Abstract][Full Text] [Related]
3. Urine TMPRSS2: ERG Fusion Transcript as a Biomarker for Prostate Cancer: Literature Review.
Sanguedolce F; Cormio A; Brunelli M; D'Amuri A; Carrieri G; Bufo P; Cormio L
Clin Genitourin Cancer; 2016 Apr; 14(2):117-21. PubMed ID: 26774207
[TBL] [Abstract][Full Text] [Related]
4. Current early diagnostic biomarkers of prostate cancer.
Qu M; Ren SC; Sun YH
Asian J Androl; 2014; 16(4):549-54. PubMed ID: 24830695
[TBL] [Abstract][Full Text] [Related]
5. Blood-based and urinary prostate cancer biomarkers: a review and comparison of novel biomarkers for detection and treatment decisions.
Hendriks RJ; van Oort IM; Schalken JA
Prostate Cancer Prostatic Dis; 2017 Mar; 20(1):12-19. PubMed ID: 27922627
[TBL] [Abstract][Full Text] [Related]
6. [Epigenetic markers of early diagnostics of prostate cancer.].
Peshkov MN
Klin Lab Diagn; 2018; 63(10):605-609. PubMed ID: 30768880
[TBL] [Abstract][Full Text] [Related]
7. Using Genetic and Epigenetic Markers to Improve Differential Diagnosis of Prostate Cancer and Benign Prostatic Hyperplasia by Noninvasive Methods in Mexican Patients.
Sánchez BE; Aguayo A; Martínez B; Rodríguez F; Marmolejo M; Svyryd Y; Luna L; Muñoz LA; Jiménez MA; Sotomayor M; Vargas V F; Mutchinick OM
Clin Genitourin Cancer; 2018 Aug; 16(4):e867-e877. PubMed ID: 29571584
[TBL] [Abstract][Full Text] [Related]
8. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
9. Serum multi-cytokines screening identifies TRAIL and IL-10 as probable new biomarkers for prostate health index diagnostic utility adjustment in grey zone aggressive prostate cancer detection: A single-center data in China.
Chen H; Zhou J; Luo J; Wu Y; Qian Y; Shi Y; Qu F; Shi B; Ding J; Cui X; Yu Y
Front Immunol; 2022; 13():901176. PubMed ID: 36059480
[TBL] [Abstract][Full Text] [Related]
10. Prostate Health Index (Phi) and Prostate Cancer Antigen 3 (PCA3) significantly improve prostate cancer detection at initial biopsy in a total PSA range of 2-10 ng/ml.
Ferro M; Bruzzese D; Perdonà S; Marino A; Mazzarella C; Perruolo G; D'Esposito V; Cosimato V; Buonerba C; Di Lorenzo G; Musi G; De Cobelli O; Chun FK; Terracciano D
PLoS One; 2013; 8(7):e67687. PubMed ID: 23861782
[TBL] [Abstract][Full Text] [Related]
11. Prostate Cancer Detection and Prognosis: From Prostate Specific Antigen (PSA) to Exosomal Biomarkers.
Filella X; Foj L
Int J Mol Sci; 2016 Oct; 17(11):. PubMed ID: 27792187
[TBL] [Abstract][Full Text] [Related]
12. Novel Diagnostic Biomarkers of Prostate Cancer: An Update.
Anceschi U; Tuderti G; Lugnani F; Biava PM; Malossini G; Luciani L; Cai T; Marsiliani D; Filianoti A; Mattevi D; Costantini M; Misuraca L; Simone G
Curr Med Chem; 2019; 26(6):1045-1058. PubMed ID: 30215331
[TBL] [Abstract][Full Text] [Related]
13. Semen as a rich source of diagnostic biomarkers for prostate cancer: latest evidence and implications.
Mao C; Ding Y; Xu N
Mol Cell Biochem; 2022 Jan; 477(1):213-223. PubMed ID: 34655417
[TBL] [Abstract][Full Text] [Related]
14. Urinary microRNA-based signature improves accuracy of detection of clinically relevant prostate cancer within the prostate-specific antigen grey zone.
Salido-Guadarrama AI; Morales-Montor JG; Rangel-Escareño C; Langley E; Peralta-Zaragoza O; Cruz Colin JL; Rodriguez-Dorantes M
Mol Med Rep; 2016 Jun; 13(6):4549-60. PubMed ID: 27081843
[TBL] [Abstract][Full Text] [Related]
15. Diagnostic and prognostic value of serum miR-15a and miR-16-1 expression among egyptian patients with prostate cancer.
Zidan HE; Abdul-Maksoud RS; Elsayed WSH; Desoky EAM
IUBMB Life; 2018 May; 70(5):437-444. PubMed ID: 29522280
[TBL] [Abstract][Full Text] [Related]
16. Comparative Study of Blood-Based Biomarkers, α2,3-Sialic Acid PSA and PHI, for High-Risk Prostate Cancer Detection.
Ferrer-Batallé M; Llop E; Ramírez M; Aleixandre RN; Saez M; Comet J; de Llorens R; Peracaula R
Int J Mol Sci; 2017 Apr; 18(4):. PubMed ID: 28420168
[TBL] [Abstract][Full Text] [Related]
17. [Non- PSA serum markers for the diagnosis of PCa].
Mengual L; Musquera M; Ciudin A; Ribal MJ
Arch Esp Urol; 2015 Apr; 68(3):229-39. PubMed ID: 25948796
[TBL] [Abstract][Full Text] [Related]
18. Urinary biomarkers in prostate cancer detection and monitoring progression.
Wu D; Ni J; Beretov J; Cozzi P; Willcox M; Wasinger V; Walsh B; Graham P; Li Y
Crit Rev Oncol Hematol; 2017 Oct; 118():15-26. PubMed ID: 28917266
[TBL] [Abstract][Full Text] [Related]
19. Novel Biomarkers for Prostate Cancer Detection and Prognosis.
Filella X; Foj L
Adv Exp Med Biol; 2018; 1095():15-39. PubMed ID: 30229547
[TBL] [Abstract][Full Text] [Related]
20. Comparative assessment of urinary prostate cancer antigen 3 and TMPRSS2:ERG gene fusion with the serum [-2]proprostate-specific antigen-based prostate health index for detection of prostate cancer.
Stephan C; Jung K; Semjonow A; Schulze-Forster K; Cammann H; Hu X; Meyer HA; Bögemann M; Miller K; Friedersdorff F
Clin Chem; 2013 Jan; 59(1):280-8. PubMed ID: 23213079
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]